Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 15, 2025Journal of Applied Pharmaceutical ScienceOpen Access

Discovery of pyrazole–pyrazoline derivatives as VEGFR-2 kinase inhibitors: In silico approach

View Full Paper
Ask AI
Bookmark
Share

Authors

DWDeepali M. WanodeRashtrasant Tukadoji Maharaj Nagpur UniversityKBKumud BhendarkarRashtrasant Tukadoji Maharaj Nagpur UniversityPKPramod B. KhedekarRashtrasant Tukadoji Maharaj Nagpur University

Discussion

Loading...

Member takes

Overview

In silico research reveals C-64 as a potent VEGFR-2 inhibitor, suggesting improvements in cancer therapy.

Key Points

  • C-64 displayed strong binding affinity to VEGFR-2, indicating its potential as a cancer treatment.
  • Molecular docking with AutoDock Vina confirmed significant interactions of C-64 with VEGFR-2.
  • Pharmacokinetic predictions using SwissADME and pkCSM highlighted C-64's favorable drug-like properties.
  • C-64's low toxicity and high gastrointestinal absorption position it well for further research.

Cite This Study

Wanode et al. (2025) studied this question.

synapsesocial.com/papers/68efa18f9d05deea71d13f49https://doi.org/10.7324/japs.2026.256031
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Development and assessment of novel pyrazole–thiadiazol hybrid derivatives as VEGFR-2 inhibitors: design, synthesis, anticancer activity evaluation, molecular docking, and molecular dynamics simulation2024 · 2 citations
  2. 2New 5-(pyridin-3-yl)-1,3,4-oxadiazoles derivatives as VEGFR2 inhibitors: in silico study, synthesis, and cytotoxicity evaluation2026 · 1 citations
  3. 3VEGFR‐2 Targeting Oxadiazole‐Pyrazole Hybrids: Synthesis, Molecular Docking, and Cytotoxic Evaluation in Cancer Cells2026
  4. 4Rational Drug Discovery for Isoxazole Based VEGFR2 Inhibition2024
  5. 5Synthesis, cytotoxicity assessment and molecular docking of novel thienyl-pyrazoles as VEGFR2 Inhibitors.2024 · 4 citations